Loading…
Loading…
West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
EXTON, Pa., Oct. 19, 2026 /PRNewswire/ -- On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend.
West Pharmaceutical Services WST shares have gained 36.1% year to date, significantly outperforming its industry's advancement of 7.8%. The rally reflects improving demand for high-value pharmaceutical packaging components, stronger-than-expected earnings, and an upward revision to full-year guidance.
West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $330.99 and traded as high as $379.21. West Pharmaceutical Services shares last traded at $374.9340, with a volume of 444,553 shares. Analyst
On CNBC's “Halftime Report Final Trades,” Joseph M. Terranova, senior managing director for Virtus Investment Partners, said he likes West Pharmaceutical Services, Inc. (NYSE:WST).
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.
EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 29, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
West Pharmaceutical Services remains a buy despite a demanding valuation, driven by new growth catalysts and robust financial performance. Double-digit growth from GLP-1s, HVP upgrades, and the multiyear Annex 1 regulatory opportunity underpin WST's bullish outlook. Annex 1 upgrades represent a multiyear, regulatory-driven mix shift, with only ~1B of a 6B component opportunity converted so far.